Home/Pipeline/Cabozantinib

Cabozantinib

Renal Cell Carcinoma

Phase 3ActiveCOSMIC-313

Key Facts

Indication

Renal Cell Carcinoma

Phase

Phase 3

Status

Active

Company

Exelixis

About Exelixis

Exelixis has successfully evolved from a discovery-stage biotech into a commercial leader in oncology, anchored by its flagship multi-TKI cabozantinib. The company's strategy focuses on maximizing the lifecycle of its approved assets while advancing a deep and diverse pipeline, including the promising next-generation TKI zanzalintinib and a growing biotherapeutics portfolio. With a disciplined financial approach and a seasoned leadership team, Exelixis aims to establish new therapeutic franchises and deliver long-term growth.

View full company profile

Therapeutic Areas

Oncology

Other Renal Cell Carcinoma Drugs

Drug	Company	Phase	Status
LW-02 Immunopheresis	Immunicom	Phase 2	Active
CB-839 (Telaglenastat)	Calithera Biosciences	Phase 2	Discontinued
XS008 (axitinib)	Xspray Pharma	Preclinical/Development	Disclosed, development ongoing
CDK7 allosteric inhibitor	Acellera	Pre-clinical	Early Hit
Precision Oncology - RCC	ReviveMed	Discovery	Active
Ciforadenant (CPI-444)	Angel Pharmaceuticals	Phase 1b/2	Active (via partner Corvus)
Lenvatinib (LENVIMA)	Eisai	Regulatory Review	Application Submitted in Japan for combo with belzutifan
Zanzalintinib (XL092)	Exelixis	Phase 3	Active
Casdatifan (AB521)	Arcus Biosciences	Phase 3	Enrolling
XmAb®819	Xencor	Phase 1	Active
MINC‑sunitinib	Suntec Medical	Preclinical	Active